Time to Become Negative of Three Rapid Diagnostic Tests for Malaria
Recruitment status was Recruiting
Background: Antigen-detecting rapid diagnostic tests (RDTs) for malaria provide the possibility of a parasite-based diagnosis in areas where good quality microscopy can not be achieved.
P. falciparum tests targeting the histidine-rich protein (HRP2) antigen are generally more sensitive than tests targeting the Plasmodium lactate dehydrogenase (pLDH) antigen. However, as the HRP2 antigen is eliminated from the bloodstream more slowly than the pLDH antigen, HRP2-based tests can give a positive result two weeks or more after the patient has taken an effective treatment, while pLDH tests generally turn negative a few days after. The use of an RDT positive result in a routine patient care is therefore challenged by the interpretation of whether the result is due to a lasting effect of the already treated infection or to a new infection. The interpretation might also be affected by the level of malaria transmission in the area.
Objective: The objective of this study is to estimate the proportion of positive tests in patients successfully treated for malaria (smear negative) at different time points in time after treatment, for three rapid diagnostic tests: SD Bioline Malaria Antigen P.f. (catalogue number: 05FK50-02-4), CareStart Malaria HRP2 (Pf) (catalogue number: G0141) and CareStart Malaria pLDH (PAN) (catalogue number: G0111). The study will be carried out in two settings with known low and high malaria transmission levels in order to provide guidance of interpretation of a RDT positive result depending on the intensity of malaria transmission.
Secondary objectives will be to measure the sensitivity and specificity of the malaria rapid tests compared to smear microscopy, to estimate the median time to become negative for each of the tests and to estimate the proportion of positive tests and the median time to become negative according to the initial parasitaemia and the presence of gametocytes.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Time to Become Negative of Three Rapid Diagnostic Tests for Malaria in Children Under 5 Years of Age. Evaluation in Two Different Malaria Epidemiological Settings in Greater Mbarara District, South Western Uganda|
- To estimate the proportion of positive tests in patients successfully treated for malaria (smear negative) at different time points after treatment, for three rapid diagnostic tests: two HRP2 test and one pLDH test. [ Time Frame: day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake ] [ Designated as safety issue: No ]
- To measure the sensitivity and specificity of the malaria rapid tests compared to smear microscopy. [ Time Frame: The day of patient's enrollment only (day 0) ] [ Designated as safety issue: No ]
- To estimate the median time to become negative for each of the rapid diagnostic test. [ Time Frame: day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake ] [ Designated as safety issue: No ]
- To estimate the proportion of positive tests among smear negative results and the median time to become negative according to the initial parasitaemia and the presence of gametocytes. [ Time Frame: day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||September 2011|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Children with a clinical diagnosis of malaria.
Children under 5 years of age who attend to the consultation service of the selected health centres and for which a clinical diagnosis of malaria was made.
The study population will be patients under 5 years of age who attend the consultation service of one health centre of Mbarara municipality (low transmission setting) and one health centre in Kazo sub-county (high transmission setting) and for whom the clinical diagnosis of malaria is confirmed by smear microscopy and with at least one positive RDT. Patients with general signs of danger of severe malaria or who took a full course of antimalarial treatment in the previous 2 weeks will be excluded. Written consent will be sought from all participants.
A total of 212 patients will be included in each setting. The sample size was based of a minimum accuracy of 8% around a proportion of 50% positive RDTs to which a 15% was added for patients who will not be positive for all RDTs or will be secondarily excluded from the analysis.
A three-day artemether-lumefantrine will be given to enrolled cases and treatment intake will be supervised. RDTs and a blood smear microscopy will be repeated at day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after inclusion until all RDTs become negative. Follow-up will not last longer than 42 days.
The proportion and 95% confidence intervals of positive tests among patients with a negative thick smear will be calculated for each day of follow-up. Moreover the investigators will identify for each test a regression model to estimate the number of days required to obtain a 50, 25, 10 and 5% probability of having a false positive RDT result.
Sensitivity, specificity, positive and negative predictive values will be estimated for each RDT independently using the result of microscopy as a reference. The analysis will be performed using the day 0 results for all patients enrolled in the study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01325974
|Contact: Carolyn Nabasumba, MDemail@example.com|
|Contact: Francesco Grandesso, MScfirstname.lastname@example.org|
|Kazo level 4 health centre||Recruiting|
|Kazo, Greater Mbarara District, Uganda|
|Contact: Carolyn Nabasumba, MD +259774516527 email@example.com|
|Mbarara Municipality level 2 health centre||Recruiting|
|Mbarara, Greater Mbarara district, Uganda|
|Contact: Carolyn Nabasumba, MD +256774516527 firstname.lastname@example.org|
|Principal Investigator:||Francesco Grandesso, MSc||Epicentre|
|Study Chair:||Carolyn Nabasumba, MD||Epicentre|
|Study Chair:||Yap Boom, MSc, PhD||Epicentre|
|Study Chair:||Anne-Laure Page, PhD||Epicentre|
|Study Chair:||Mathieu Bastard, MSc||Epicentre|
|Study Director:||Jean-François Etard, MD, PhD||Epicentre|